Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TENORMIN | TWi Pharmaceuticals | N-018240 RX | 1982-01-01 | 3 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TENORETIC 100 | TWi Pharmaceuticals | N-018760 RX | 1984-06-08 | 1 products, RLD, RS |
TENORETIC 50 | TWi Pharmaceuticals | N-018760 RX | 1984-06-08 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
atenolol | ANDA | 2025-02-21 |
atenolol and chlorthalidone | ANDA | 2024-11-25 |
atenolol scopolamine | unapproved drug other | 2014-10-15 |
tenoretic | New Drug Application | 2024-01-31 |
tenormin | New Drug Application | 2024-08-05 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | 1 | — | — | 3 |
Drug common name | Atenolol |
INN | atenolol |
Description | Atenolol is an ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent. It has a role as a beta-adrenergic antagonist, an anti-arrhythmia drug, an antihypertensive agent, a sympatholytic agent, a xenobiotic and an environmental contaminant. It is a member of ethanolamines, a monocarboxylic acid amide and a propanolamine. |
Classification | Small molecule |
Drug class | beta-blockers (propranolol type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)NCC(O)COc1ccc(CC(N)=O)cc1 |
PDB | — |
CAS-ID | 29122-68-7 |
RxCUI | — |
ChEMBL ID | CHEMBL24 |
ChEBI ID | 2904 |
PubChem CID | 2249 |
DrugBank | DB00335 |
UNII ID | 50VV3VW0TI (ChemIDplus, GSRS) |